"We are very excited about this new product and the significant contributions it will make to the biomarker research field of guiding drug development and diagnostic research. Proseek delivers excellent assay performance from a simple working procedure. It is a specific, sensitive and reliable method. It also offers the benefits of detection using real-time PCR, allowing quantification of both relative and absolute protein levels. In early testing this product has been well received by the scientific community both in industry and academia,£ says Dr Simon Fredriksson, Chief Scientific Officer at Olink Bioscience.

"the low sample consumption and overall immunoassay permformance of Proseek has enabled us to access precious and limited biobanked plasma samples, a commonly recurring problem with standard technologies which use 50-100 fold more material. We are now able to perform novel biomarker research studies with the goal of improving early detection of breast and colorectal cancer," says Proseek use Dr Jan Stevang, Head of Research, University of Copenhagen.

The Proseek reagents are based on PEA, which is a proximity extension assay technology. A pair of oligonucleotide labeled antibodies, Proseek probes, are allowed to pair-wise bind to the target protein present in the sample in a homogenous assay, without washing steps. When the two Proseek probes are in close proximity, a new PCR target sequence is formed by a proximity dependent DMA polymerization event. The resulting new sequence is subsequently detected and quantified using standard real-time PCR.